| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
45,560,000 |
| Market
Cap: |
12.06(M) |
| Last
Volume: |
1,167,076 |
Avg
Vol: |
529,624 |
| 52
Week Range: |
$0.2646 - $0.2646 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
64,516 |
174,516 |
| Total Buy Value |
$0 |
$0 |
$90,484 |
$246,299 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Techno-Rov Holdings (1993) Ltd |
10% Owner |
– – • |
2006-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
6,186,046 |
6,186,046 |
|
- |
|
| Toussia-Cohen Sharon |
Director |
– • • |
2006-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
6,556,381 |
6,556,381 |
|
- |
|
| Sheratzki Eyal |
Director |
– • • |
2006-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
14,466,319 |
14,466,319 |
|
- |
|
| Hurvitz Eli |
Director |
– • – |
2006-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
2,886,447 |
2,886,447 |
|
- |
|
| Bio-Cell Ltd |
10% Owner |
– – • |
2006-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
14,466,319 |
14,466,319 |
|
- |
|
| Frost Phillip Md Et Al |
Director |
– • • |
2006-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
7,348,675 |
7,645,228 |
|
- |
|
| Frost Phillip Md Et Al |
officerTitle |
– – • |
2005-11-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,965,428 |
|
- |
|
182 Records found
|
|
Page 8 of 8 |
|
|
